وهذا اول خبر عنه
Press Release Source: ADVENTRX Pharmaceuticals, Inc.
ADVENTRX Presents Positive Thiovir Preclinical Results
Monday April 3, 4:00 am ET
SAN DIEGO, April 3 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX - News) announced today that data were presented showing strong antiviral synergy without added cytotoxicity with combinations of Thiovir(TM) and zidovudine (AZT) in a series of in vitro tests serving as models for human immunodeficiency virus (HIV) infection. The data were presented on Friday, March 31 at the HIV Pathogenesis Meeting, in Keystone, Colorado. The abstract entitled "Synergistic antiviral activity and additive cytotoxicity of Thiovir combined with zidovudine" was presented by Shani Waninger, Ph.D., associate director of research and development for ADVENTRX. Thiovir is a broad spectrum antiviral and oral prodrug for foscarnet, a drug approved to treat opportunistic infections in HIV/AIDS patients. Thiovir is being developed as a reverse transcriptase inhibitor to be used as a component of highly active antiretroviral therapy (HAART) for HIV/AIDS and as a potential antiviral therapy for avian flu.